Non-Small Cell Lung Cancer Treatment Market Value to Exceed $7.9 Billion by 2020
The global Non-Small Cell Lung Cancer (NSCLC) treatment market value will increase from $5.1 billion in 2013 to slightly over $7.9 billion by 2020, expanding at a Compound Annual Growth Rate (CAGR) of 6.6%, according to business intelligence provider GBI Research.
The company’s latest report, Non-Small Cell Lung Cancer Market to 2020 – New Therapies to Enhance Treatment Segmentation and Drive Growth in an Increasingly Competitive Market, states that this growth will be driven primarily by the introduction of numerous premium therapies, particularly in second-line and squamous cell treatment settings, which either replace or combine with generic chemotherapies.
Other key drivers will be the increased uptake of currently marketed therapies, such as Gilotrif, and the lack of marked drug patent expirations until the end of the forecast period.
Joshua Libberton, Analyst for GBI Research, says: “There will be numerous new drug market entries by 2020, and while some will only have a low impact in crowded sectors, other new approvals will benefit patient subpopulations that are untreated by targeted therapies.
“Most notably, the squamous cell patient population, which currently relies on generic chemotherapy regimens only, will have access to immunotherapies such as Yervoy (ipilimumab), necitumumab and nivolumab.”
Libberton adds that while some of these drugs’ safety profiles are a concern, they have clinically demonstrated improvements or non-inferiority to the efficacy of current segment leaders. Therefore, while GBI Research forecasts that these drugs are unlikely to dominate the market and replace chemotherapy, they will offer suitable alternatives and help to diversify treatment options.
Despite considerable growth through to 2020, the report states that the NSCLC market’s upcoming patent cliff will mean limited further expansion.
Libberton explains: “Over the forecast period, the market environment will not allow premium entrants to be offset by the availability of efficacious generics. As treatment quality improves, physicians will be expected to prescribe expensive targeted therapies over generic chemotherapy options.
“However, leading drugs Avastin and Tarceva will lose patent protection in 2019 and 2020, respectively, followed by Alimta in 2021, all of which will hinder future market growth.”
The report provides an assessment of the current Non-Small Cell Lung Cancer (NSCLC) treatment market and evaluates key drivers and barriers to predict global trends to 2020. The report also provides insight into the NSCLC pipeline, including drug distribution by Phase, molecule type and mechanism of action, in addition to an analysis of strategic consolidations within the NSCLC indication, including co-development and licensing agreements.
This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GBI Research’s team of industry experts.
-ABOUT GBI RESEARCH-
GBI Research is a market-leading provider of business intelligence reports, offering actionable data and forecasts based on the insights of key industry leaders to ensure you stay up-to-date with the latest emerging trends in your markets. For more information, please contact our Press Office on +44 (0)1204 543 537 or at email@example.com. Follow us online for the latest industry updates:
Total Page Views: 1540